You are here:Home-Chemical Inhibitors & Agonists-Tyrosine Kinase-Anaplastic Lymphoma Kinase (ALK)-Ensartinib dihydrochloride
Ensartinib dihydrochloride

Chemical Structure : Ensartinib dihydrochloride

CAS No.: 2137030-98-7

Ensartinib dihydrochloride (X396, X-396)

Catalog No.: PC-21789Not For Human Use, Lab Use Only.

Ensartinib (X-396) dihydrochloride is a potent, selective and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with biochemical IC50 of <0.4 nM, inhibits MET with IC50 of 0.74 nM.

Packing Price Stock Quantity
5 mg $148 In stock
10 mg $228 In stock
25 mg $368 In stock
50 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Ensartinib (X-396) dihydrochloride is a potent, selective and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with biochemical IC50 of <0.4 nM, inhibits MET with IC50 of 0.74 nM.
Ensartinib (X-396) is more potent ALK inhibitors than PF-02341066 (PF-1066).
Ensartinib (X-396) potently inhibits H3122 lung cancer cells harboring EML4-ALK E13;A20 (variant 1) with IC50 of 15 nM, 10-fold more potent than PF-02341066.
Ensartinib (X-396) display less activity against MET than PF-1066.
Ensartinib (X-396) (25mg/kg bid) inhibits tumore growth against H3122 xenografts.
Ensartinib (X-396) is effective against multiple ALK variants found in NSCLC, including ALK mutations associated with acquired resistance to PF-1066.
Ensartinib (X-396) is synergistic with mTOR inhibitor rapamycin against ALK fusion positive lung cancer cell lines.

Physicochemical Properties

M.Wt 634.36
Formula C26H29Cl4FN6O3
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3R,5S)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide dihydrochloride

References

1. Horn L, et al. Clin Cancer Res. 2018 Jun 15;24(12):2771-2779.

2. Christine M Lovly, et al. Cancer Res. 2011 Jul 15;71(14):4920-31.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: